Shelter Pharma Limited has confirmed that there has been no deviation or variation in the utilization of proceeds from its recent preferential issue of warrants convertible into equity shares. The company raised Rs. 9.30 crore through the allotment of 88,08,000 warrants at Rs. 42.25 each on August 6, 2025.

Warrant Issuance Details

The company received 25% of the subscription amount, totaling Rs. 9,30,34,500, for the warrants issued. The funds were allocated as follows:

These allocations are in line with the objects approved in the Extraordinary General Meeting held on July 23, 2025.

Utilization of Funds

According to the Statement of Deviation and Variation provided by the company's auditors, the entire amount of Rs. 930.35 lakhs received has been utilized for working capital requirements, as per the disclosed objectives.

Future Payments

Shelter Pharma noted that the remaining 75% of the warrant subscription amount will be received within 18 months, in accordance with ICDR (Issue of Capital and Disclosure Requirements) regulations.

Financial Performance

For the half-year ended September 30, 2025, Shelter Pharma reported the following financial results:

The company's performance shows an improvement compared to the previous periods, with increased revenue and profitability.

Balance Sheet Highlights

As of September 30, 2025, Shelter Pharma's balance sheet reflects the following:

The company's financial position appears to have strengthened, with an increase in reserves and surplus, and the addition of funds from the warrant issue.

Shelter Pharma Limited continues to focus on its core business of manufacturing pharmaceuticals, with no changes reported in its segment operations. The company's management and auditors have ensured compliance with regulatory requirements, including the timely filing of financial results and utilization reports.

Shelter Pharma Limited has announced its unaudited financial results for the half year ended September 30, 2025, showcasing a mixed performance compared to the previous year. The pharmaceutical manufacturer reported a profit before tax of Rs 601.45 crore, down from Rs 967.70 crore in the corresponding period last year.

Financial Highlights

Despite the decrease in revenue and profit before tax, the company's basic earnings per share (EPS) improved to Rs 3.89, up from Rs 3.06 in the previous year, indicating a 27.1% increase.

Balance Sheet Strengthens

Shelter Pharma's balance sheet showed signs of growth:

• Total assets increased to Rs 6,689.54 crore as of September 30, 2025, up from Rs 4,833.55 crore on March 31, 2025.
• Reserves and surplus grew to Rs 3,561.47 crore from Rs 3,116.08 crore.
• The company received Rs 1,350.84 crore as money against share warrants.

Operational Performance

The cost of material consumed stood at Rs 2,490.11 crore for the half-year period. Employee benefit expenses were reported at Rs 85.40 crore, while other expenses amounted to Rs 120.72 crore.

Cash Flow and Liquidity

The company's cash and cash equivalents at the end of the period stood at Rs 527.96 crore, showing a significant increase from Rs 341.99 crore at the beginning of the year. This improvement in liquidity may provide the company with more flexibility for future investments and operations.

Corporate Governance

The Board of Directors approved these results in a meeting held on November 10, 2025. The company reported no investor complaints during the review period, reflecting positively on its investor relations practices.

Utilization of Funds

According to the auditor's report, Shelter Pharma has fully utilized the Rs 930.35 crore raised through a preferential issue of convertible warrants into equity shares for working capital requirements, with no deviation from the stated objectives.

Shelter Pharma continues to operate in the pharmaceutical manufacturing sector, facing challenges in revenue growth but maintaining profitability and strengthening its balance sheet.